Karyopharm Therapeutics

KPTI

Market cap $94.4M

Karyopharm Therapeutics Inc. (KPTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KPTI's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with  $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.

– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively – – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – NEWTON, Mass. , Oct. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into  comprehensive financing and capital structure transactions expected to provide the Company with  $100 million of financial flexibility and additional capital, extending the Company's cash runway into the second quarter of 2026 based on the Company's current operating plans.

NEWTON, Mass. , Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.

Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

– Top-Line Results Anticipated in March 2026 – NEWTON, Mass. , Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.

NEWTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees.

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $4.32 per share versus the Zacks Consensus Estimate of a loss of $3.8. This compares to a loss of $3 per share a year ago.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Brendan Twohig Strong - Corporate Participant SVP of Investor Relations & Corporate Communications - Corporate Participant Lori A. Macomber - EVP, CFO & Treasurer Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Richard A.

– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.